Compare Eaton Corporation plc (ETN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs TG Therapeutics Inc — how do they compare? Eaton Corporation plc trades at $428.87 (market cap $164.88B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Eaton Corporation plc is far larger — about 20.2× TG Therapeutics Inc's market cap, and Eaton Corporation plc pays a 1.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and TG Therapeutics Inc for 16 Days on average.
| ETN | TGTX | |
|---|---|---|
Market Cap | $164.88B | $8.16B |
Volume | 2,535,086 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $459.96 | $59.06 |
52-Week Low | $315.82 | $26.94 |
Typical Hold Time | 31 Days | 16 Days |
Enterprise Value | $185.51B | $8.37B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $430.25, down 0.25% with bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains healthy margins (12.75% net income), and benefits from strategic acquisitions in data center and aerospace markets. Analyst consensus remains strongly bullish with a $502.38 price target, though technical indicators show near-term pressure with support at $418.
ETN presents a compelling growth story driven by AI data center demand and grid modernization trends, but faces execution risks from recent acquisitions and competitive pressure from peers like Vertiv. The stock's premium valuation (P/E 43.23) requires sustained earnings growth to justify, making upcoming Q3 earnings on November 5 critical for momentum.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
